MENU
+Compare
PHIO
Stock ticker: NASDAQ
AS OF
Dec 3, 04:59 PM (EDT)
Price
$1.28
Change
+$0.05 (+4.07%)
Capitalization
13.46M

PHIO Phio Pharmaceuticals Corp Forecast, Technical & Fundamental Analysis

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells... Show more

Industry: #Biotechnology
PHIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PHIO with price predictions
Nov 28, 2025

PHIO in -10.40% downward trend, falling for three consecutive days on November 21, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PHIO declined for three days, in of 362 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for PHIO entered a downward trend on October 31, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PHIO's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 72 cases where PHIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PHIO just turned positive on November 28, 2025. Looking at past instances where PHIO's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PHIO advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .

PHIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.368) is normal, around the industry mean (27.312). P/E Ratio (0.012) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (321.020).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PHIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
PHIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of RNAi-based medical technologies and therapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Apex Drive
Phone
+1 508 767-3861
Employees
9
Web
https://www.phiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SINT3.620.35
+10.70%
SiNtx Technologies Inc.
REPL10.020.31
+3.19%
Replimune Group
PL11.770.07
+0.60%
Planet Labs PBC
K83.120.05
+0.06%
Kellanova
OXSQ1.83-0.01
-0.54%
Oxford Square Capital Corp

PHIO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PHIO has been loosely correlated with KAPA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PHIO jumps, then KAPA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHIO
1D Price
Change %
PHIO100%
-2.40%
KAPA - PHIO
53%
Loosely correlated
+3.73%
MTNB - PHIO
50%
Loosely correlated
+3.77%
TPST - PHIO
49%
Loosely correlated
-0.98%
AZTR - PHIO
48%
Loosely correlated
+2.88%
IMNN - PHIO
39%
Loosely correlated
+0.76%
More